Loading…
Phibro Animal Health Corporation is projected to rise to $41.31 by 2027, a +14% move from its current price of $36.33. PAHC is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $35.65 | $36.35 | $37.06 | +0.05% |
| Aug 3 | $35.38 | $36.37 | $37.38 | +0.11% |
| Aug 4 | $35.18 | $36.39 | $37.64 | +0.16% |
| Aug 5 | $35.02 | $36.41 | $37.85 | +0.22% |
| Aug 6 | $34.88 | $36.43 | $38.05 | +0.27% |
| Aug 7 | $34.75 | $36.45 | $38.23 | +0.32% |
| Aug 8 | $34.64 | $36.47 | $38.39 | +0.38% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $34.64 | $36.47 | $38.39 | +0.38% |
| Week 2 | $34.04 | $36.61 | $39.37 | +0.76% |
| Week 3 | $33.61 | $36.74 | $40.17 | +1.14% |
| Week 4 | $33.28 | $36.88 | $40.88 | +1.52% |
| Week 5 | $33.00 | $37.02 | $41.54 | +1.90% |
| Week 6 | $32.76 | $37.16 | $42.15 | +2.29% |
| Week 7 | $32.55 | $37.30 | $42.74 | +2.68% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.
It offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal health and performance, food safety, and animal welfare; and engages in developing, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, copper, manganese, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals.
Additionally, the company offers specialty ingredients for use in personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc.
and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 1946 and is headquartered in Teaneck, New Jersey.
Phibro Animal Health Corporation (PAHC) is a healthcare-focused stock with a current price of $36.37 and a market cap of $1.48B. It is ranked 2180 in market capitalization among listed equities. The stock trades in a market that shows a 30-day price range roughly from $31.64 to $41.80, reflecting near-term volatility.
The latest price and the near-term outlook align with a neutral-to-bullish setup as the company moves through its multi-year forecast.
A major floor 22.4% below — a decisive break under it would weaken the trend.
The nearest floor, 16.0% below — buyers have tended to step in here.
Price is pressing into resistance (1.7% away) — a breakout level to watch.
A major ceiling 64.0% above — clearing it would confirm fresh momentum.
Key PAHC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PAHC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $36.27 | Buy | $36.05 | Buy |
| MA 10 | $35.01 | Buy | $35.33 | Buy |
| MA 20 | $34.09 | Buy | $34.47 | Buy |
| MA 50 | $32.75 | Buy | $35.45 | Buy |
| MA 100 | $42.06 | Sell | $38.43 | Sell |
| MA 200 | $42.63 | Sell | $39.14 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 62.54 | Neutral |
| Stoch RSI (14) | 75.02 | Neutral |
| CCI (20) | 131.55 | Buy |
| Williams %R (14) | -15.86 | Info |
| MACD (12,26,9) | 0.43 | Buy |
| ROC (12) | 7.68 | Buy |
| Bollinger %B (20,2) | 0.89 | Neutral |
| Stochastic %K (14) | 84.14 | Sell |
| TRIX (15) | 0.20 | Buy |
| Awesome (5,34) | 3.17 | Buy |
| Ultimate (7,14,28) | 77.71 | Sell |
| Momentum (10) | 3.02 | Buy |
| Aroon Osc (25) | 80.00 | Buy |
| Hull MA (9) | 37.25 | Sell |
| ADX (14) | 16.72 | Neutral |
| ATR (14) | 0.62 | Info |
Technically, PAHC shows a bullish tilt in the near term with an RSI of 60. The 30-day price range runs from $31.64 to $41.80, suggesting ample room for movement within a relatively wide band. The stock is trading above its 50-day simple moving average of $32.63 and below its 200-day simple moving average of $42.65, indicating mixed intermediate-term momentum with a bullish bias.
Support is identified around $30.53 and resistance near $35.24, framing a near-term trading range that sits above the current price of $36.37. Overall, sentiment for the near term is bullish, with a stable to constructive projection as market participants digest earnings and industry dynamics."
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $28.52 | $36.33 | $45.80 | 0% | Neutral | |
| $33.80 | $41.31 | $52.79 | +14% | Neutral | |
| $35.60 | $44.36 | $58.29 | +22% | Bullish | |
| $38.49 | $48.74 | $65.47 | +34% | Bullish | |
| $40.15 | $51.56 | $70.55 | +42% | Bullish | |
| $45.23 | $58.81 | $81.79 | +62% | Bullish | |
| $53.79 | $70.77 | $99.86 | +95% | Bullish | |
| $58.71 | $78.09 | $111.67 | +115% | Bullish | |
| $62.68 | $84.23 | $121.94 | +132% | Bullish | |
| $62.38 | $84.65 | $123.95 | +133% | Bullish | |
| $98.28 | $139.34 | $214.08 | +284% | Bullish | |
| $153.86 | $234.66 | $387.14 | +546% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $28.52 | $36.33 | $43.35 | +0.00% |
| September 2026 | $31.51 | $36.97 | $44.38 | +1.77% |
| October 2026 | $32.37 | $38.16 | $46.16 | +3.21% |
| November 2026 | $32.27 | $38.19 | $46.49 | +0.09% |
| December 2026 | $31.50 | $37.42 | $45.80 | -2.04% |
Click any year to see its month-by-month PAHC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The PAHC price prediction for 2026 points to an average of $36.33 (low $28.52, high $45.80) — a potential gain of 0% on today's $36.33. A consolidation phase looks the most probable path here.
In 2027, PAHC is projected to trade between $33.80 and $52.79, averaging $41.31 — a potential gain of +14% from today's $36.33. That is up +14% on the projected 2026 average. Price action looks broadly range-bound.
Phibro Animal Health Corporation's 2028 outlook centres on $44.36, within a $35.60 to $58.29 range. That is up +7% on the projected 2027 average. That marks a +22% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, PAHC could reach as high as $65.47, with a base case around $48.74 and support toward $38.49 — roughly +34% from $36.33. Momentum favours further upside here.
Expect PAHC to range from $40.15 to $70.55 through 2030. The $51.56 average target implies a +42% move from current prices. That is up +6% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The PAHC price prediction for 2031 points to an average of $58.81 (low $45.23, high $81.79) — a potential gain of +62% on today's $36.33. Momentum favours further upside here.
In 2032, PAHC is projected to trade between $53.79 and $99.86, averaging $70.77 — a potential gain of +95% from today's $36.33. That is up +20% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Phibro Animal Health Corporation's 2033 outlook centres on $78.09, within a $58.71 to $111.67 range. That is up +10% on the projected 2032 average. That marks a +115% change versus current levels. Momentum favours further upside here.
By 2034, PAHC could reach as high as $121.94, with a base case around $84.23 and support toward $62.68 — roughly +132% from $36.33. Buyers look set to stay in control over this stretch.
Expect PAHC to range from $62.38 to $123.95 through 2035. The $84.65 average target implies a +133% move from current prices. That is up 0% on the projected 2034 average. Momentum favours further upside here.
The PAHC price prediction for 2040 points to an average of $139.34 (low $98.28, high $214.08) — a potential gain of +284% on today's $36.33. Buyers look set to stay in control over this stretch.
In 2050, PAHC is projected to trade between $153.86 and $387.14, averaging $234.66 — a potential gain of +546% from today's $36.33. That is up +68% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in PAHC today (≈ 27.525461 PAHC) could be worth
$6,459.01
+$5,459.01 (+546%) by 2050 · US Dollar
Based on the average projected PAHC price of $234.66 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PAHCwould be worth at today's price.
$1,000 invested in PAHC on Jul 31, 2025 (≈ 37.735849 PAHC) would be worth
$1,370.94
+$370.94 (+37.1%) today · 1.37× · US Dollar
Based on a PAHC entry price of $26.5 vs. today's $36.33.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $34.03 | $1,067.43 | +6.7% |
| 1 month ago | $32.1 | $1,131.78 | +13.2% |
| 3 months ago | $54.89 | $661.87 | -33.8% |
| 6 months ago | $41.91 | $866.86 | -13.3% |
| 1 year ago | $26.5 | $1,370.94 | +37.1% |
| All time (5.0y) ago | $24.33 | $1,493.22 | +49.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PAHC forecast.
Our base-case forecast reaches $73.00 around 2033.
Implied market cap at $73.00: $1.54B
The multi-year forecast presents a clear upward trajectory for PAHC, with the average price rising from $36.37 in 2026 to higher levels in later years. The projections show an average price of $51.87 in 2030, supported by a 42.6% ROI in that year, and a bullish sentiment. By 2040 the average forecast rises to $139.97 with a substantial 284.9% ROI, and by 2050 the average is $235.85 with a 548.5% ROI, all bearing bullish sentiment.
In earlier years, the forecast shows continued upside with the 2027 average at $41.52 (ROI 14.2%), 2028 at $44.42 (ROI 22.1%), and 2029 at $48.86 (ROI 34.3%). By 2031 the average is $58.95 and by 2032 $71.17 (ROI 95.7%), continuing a bullish trend through mid-decade and beyond. The long-horizon outlook highlights strong upside potential, albeit with the usual uncertainty surrounding price forecasts.
These figures are estimates, not guarantees, and actual results may differ.
Overall, the forecast paints a rising path to very high levels by 2040 and 2050, supported by positive sentiment in later years. The near-term to mid-term focus shows growing averages and expanding ROI, underscoring upside potential alongside inherent market volatility (annualized volatility of 40%). Risks include price variability and macro factors that can affect commodity and animal-health sectors, so investors should consider these projections as directional and not guaranteed outcomes.
Tap a question to reveal the answer.
Avg $51.87; min $39.99; max $71.91; ROI 42.6%; sentiment bullish.
Forecasts show rising averages and positive ROI over time: 2027 avg $41.52 (ROI 14.2%), 2028 avg $44.42 (ROI 22.1%), 2029 avg $48.86 (ROI 34.3%), 2030 avg $51.87 (ROI 42.6%), 2040 avg $139.97 (ROI 284.9%), 2050 avg $235.85 (ROI 548.5%), with bullish sentiment in later years. These are estimates, not guarantees.
Yes, the forecast shows a 2032 max of $101.97 and a 2032 avg of $71.17, with higher peaks later such as 2040 max $219.58 and 2050 max $399.03.
Current price $36.37; Market cap $1.48B.
Low $31.64; High $41.80.
Phibro Animal Health Corporation Community Discussion
0Share your Phibro Animal Health Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.